Skip to main content Skip to navigation
R718 Mouse Anti-Human CD8b
R718 Mouse Anti-Human CD8b
Multiparameter flow cytometric analysis using BD OptiBuild™ R718 Mouse Anti-Human CD8b antibody (Cat. No. 751867) on Human peripheral blood. Flow cytometry was performed using a BD LSRFortessa™ X-20  Flow Cytometer System.
Multiparameter flow cytometric analysis using BD OptiBuild™ R718 Mouse Anti-Human CD8b antibody (Cat. No. 751867) on Human peripheral blood. Flow cytometry was performed using a BD LSRFortessa™ X-20  Flow Cytometer System.
Product Details
Down Arrow Up Arrow


BD OptiBuild™
CD8B; CD8B1; CD8 beta; CD8β; Leu2; Ly3; LYT3
Human (Tested in Development)
Mouse BALB/c IgG2a, κ
CD8+ suppressor T-cell
Flow cytometry (Qualified)
0.2 mg/ml
II T95
926
Aqueous buffered solution containing ≤0.09% sodium azide.
RUO


Preparation And Storage

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody. Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.

Recommended Assay Procedures

BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.

Product Notices

  1. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
  2. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
  3. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
  4. An isotype control should be used at the same concentration as the antibody of interest.
  5. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  6. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
  7. Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
  8. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
  9. This product is provided under an Agreement between BIOTIUM and BD Biosciences. This product, and only in the amount purchased by buyer, may be used solely for buyer’s own internal research, in a manner consistent with the accompanying product literature. No other right to use, sell or otherwise transfer (a) this product, or (b) its components is hereby granted expressly, by implication or by estoppel. This product is for research use only. Diagnostic uses require a separate license from Biotium, Inc. For information on purchasing a license to this product including for purposes other than research, contact Biotium, Inc., 3159 Corporate Place, Hayward, CA 94545, Tel: (510) 265-1027. Fax: (510) 265-1352. Email: btinfo@biotium.com.
  10. Alexa Fluor™ is a trademark of Life Technologies Corporation.
  11. For U.S. patents that may apply, see bd.com/patents.
751867 Rev. 2
Antibody Details
Down Arrow Up Arrow
2ST8.5H7

The 2ST8.5H7 monoclonal antibody specifically recognizes an epitope formed by the combination of CD8 alpha and beta chains. The majority of peripheral blood CD8+ T lymphocytes expresses a CD8αβ heterodimer (32, 30 kilodaltons (kDa)), while CD8+CD16+ natural killer (NK) cells and CD8+ TCR γδ+ T lymphocytes express CD8αα homodimers. The 2ST8.5H7 antibody can therefore be used to selectively bind to CD8+ T cells while excluding CD8+ NK cells. CD8 binds to class I major histocompatibility (MHC) molecules, resulting in increased adhesion between the CD8+ T lymphocytes and target cells. Binding of CD8 to class I MHC molecules enhances the activation of resting T lymphocytes. CD8 is coupled to a protein tyrosine kinase, p56lck. The CD8:p56lck complex can play a role in T-lymphocyte activation through mediation of the interactions between CD8 and the CD3/TCR complex. The CD8β antigen is present on the human suppressor/cytotoxic T-lymphocyte subset. The CD8 antigen is expressed on 19% to 48% of normal peripheral blood lymphocytes and 60% to 85% of normal thymocytes. The 2ST8.5H7 antibody crossreacts with lymphocytes of some nonhuman primate species.

751867 Rev. 2
Format Details
Down Arrow Up Arrow
R718
The BD Horizon™ Red 718 (R718) Dye is part of the BD red family of dyes. It is a small organic fluorochrome with an excitation maximum (Ex Max) at 695-nm and an emission maximum (Em Max) at 718-nm. Driven by BD innovation, R718 is designed to be excited by the red laser (627–640-nm) and detected using an optical filter centered near 720-nm (e.g., a 720/40-nm bandpass filter). R718 is a brighter alternative to Alexa Fluor™ 700. R718 is also a bright small molecule alternative to APC-R700 with lower spread into the APC detector. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
altImg
R718
Red 627-640 nm
695 nm
718 nm
751867 Rev.2
Citations & References
Down Arrow Up Arrow
View product citations for antibody "751867" on CiteAb

Development References (6)

  1. Hambor JE, Weber MC, Tykocinski ML, Kaplan DR. Regulation of allogeneic responses by expression of CD8 alpha chain on stimulator cells.. Int Immunol. 1990; 2(9):879-83. (Clone-specific: Flow cytometry). View Reference
  2. Hori T, Cupp J, Wrighton N, Lee F, Spits H. Identification of a novel human thymocyte subset with a phenotype of CD3- CD4+ CD8 alpha + beta-1. Possible progeny of the CD3- CD4- CD8- subset.. J Immunol. 1991; 146(12):4078-84. (Clone-specific: Flow cytometry). View Reference
  3. Ledbetter JA, Evans RL, Lipinski M, Cunningham-Rundles C, Good RA, Herzenberg LA. Evolutionary conservation of surface molecules that distinguish T lymphocyte helper/inducer and cytotoxic/suppressor subpopulations in mouse and man. J Exp Med. 1981; 153(2):310-323. (Biology). View Reference
  4. Moebius U. Cluster report: CD8. In: Knapp W. W. Knapp .. et al., ed. Leucocyte typing IV : white cell differentiation antigens. Oxford New York: Oxford University Press; 1989:342-343.
  5. Shiue L, Gorman SD, Parnes JR. A second chain of human CD8 is expressed on peripheral blood lymphocytes.. J Exp Med. 1988; 168(6):1993-2005. (Clone-specific: Flow cytometry). View Reference
  6. Terry LA, DiSanto JP, Small TN, Flomenberg N. Differential expression of the CD8 and Lyt-3 antigens on a subset of human T-cell receptor γ/δ-bearing lymphocytes. In: Knapp W. W. Knapp .. et al., ed. Leucocyte typing IV : white cell differentiation antigens. Oxford New York: Oxford University Press; 1989:345-346.
View All (6) View Less
751867 Rev. 2

 

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.